Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 6Active not recruiting 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Endocrine 2Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 501Carcinoma, Renal Cell 165Urinary Bladder Neoplasms 135Carcinoma, Transitional Cell 71Carcinoma, Non-Small-Cell Lung 57Kidney Neoplasms 56Melanoma 53Breast Neoplasms 51Ovarian Neoplasms 43Neoplasms 41Neoplasm Metastasis 40Colorectal Neoplasms 38Lung Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Sarcoma 24Endometrial Neoplasms 24Triple Negative Breast Neoplasms 21Pancreatic Neoplasms 19Esophageal Neoplasms 18Carcinoma, Hepatocellular 17Wilms Tumor 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Urologic Neoplasms 14Colonic Neoplasms 14Urethral Neoplasms 13Ureteral Neoplasms 13

Interventions

pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Small Cell × Genitourinary × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 1 FDA
DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡